Melatonin Hormone Acts on Cells of Maternal Blood and Placenta From Diabetic Mothers

Martino B. Pierre Louis, Danielle Cristina Honorio França, Adriele Athaides Queiroz, Iracema de Mattos Paranhos Calderon, Eduard Luzia França and Adenilda Cristina Honorio-França*

1 Institute of Biological and Health Science, Federal University of Mato Grosso, Barra do Garças, Brazil, 2 Medical Course, State University of Mato Grosso, Cáceres, Brazil, 3 Gynecology, Obstetrics and Mastology Posgraduate Programme, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil

Changes in glucose metabolism of diabetic mothers affect immunological components, proinflammatory factors, and placental hypervascularization that can induce cell death. The hormone melatonin has been identified as a potential modulating agent. The aim of this study was to analyze the oxidative process and the apoptosis in maternal blood and placental cells modulated by melatonin from diabetic mothers. The groups were 40 pregnant women divided into non-diabetic (ND) and type 2 diabetes mellitus (T2DM) groups. Blood and placental cells were obtained by density gradient and maintained in culture treated or not with melatonin (100 ng/mL) for 24 h (37°C, 5% CO2).

Oxidative stress was evaluated by superoxide release and CuZn superoxide dismutase (SOD). Apoptosis was assessed by flow cytometry. Maternal hyperglycemia increased superoxide release and apoptosis in MN cells from maternal blood and reduced SOD level and SOD/O2- ratio. Melatonin reduced oxidative stress and apoptosis rates in MN cells in the blood of diabetic mothers. There was a reduction in SOD and SOD/O2- ratio in the placental extravillous layer, and melatonin restored the concentrations of this enzyme. There was greater superoxide release, reduced SOD/O2- ratio, and apoptosis in MN cells placental villous layer. Melatonin increased apoptosis rates in the placental villous layer from hyperglycemic mothers. These data suggest that hyperglycemia altered the processes oxidative in blood and placenta from hyperglycemic mothers. These changes reflected in the mechanisms of induction of apoptosis, especially in the vascularized layers of the placenta, and were modulated by melatonin.

Keywords: apoptosis, mononuclear cells, diabetes, melatonin, placenta, blood

INTRODUCTION

The placenta is a highly vascularized transitory organ from fetal–maternal tissues that play important functions in maintaining pregnancy and promoting fetal development (Moore and Persaud, 2008). This organ plays a critical role in immunoregulation (Hara et al., 2016) and sources cells from maternal and fetal origin. These cells present molecules that have an essential role in maternal–fetal tolerance (Guleria and Sayegh, 2007).

The placenta can alter cell and cytokine levels from maternal blood before passing them on to the fetus. The inflammatory environment influences this mechanism due to hyperglycemia...
Maternal hyperglycemia may trigger structural and physiological responses to assure maternal–fetal exchanges and fetal oxygen delivery and alter cellular oxidative metabolism at the maternal–fetal interface (Gauster et al., 2011) with an imbalance between the generation of reactive oxygen species (ROS) and antioxidant defense.

These changes cause modulation of cellular proteins, lipids, and DNA, affecting cellular behavior and differentiation and inducing apoptosis and cellular damage (Espinosa-Diez et al., 2015). In addition, in the placenta villous layer of diabetic mothers, memory T cells and Fas expression are reduced, which may alter T cell apoptosis and regulate maternal–fetal immune tolerance (Queiroz et al., 2019).

The placenta, through maternal blood, establishes an interface for the exchange of nutrients and gases with the fetus, and the production of specific regulatory molecules with metabolic and endocrine activities, with the participation of several hormones (Benirschke, 2000). For example, the hormone melatonin has effects on pancreatic insulin secretion (Fu et al., 2013) and cellular oxidative metabolism (Fernandes et al., 2019), and antioxidant action (Arendt and Skene, 2005; Morceli et al., 2013).

There is evidence of the importance of melatonin as a potent immunomodulatory agent that improves the functional activity of cells (França et al., 2008; Honorio-França et al., 2009, Honorio-França et al., 2013). In addition, melatonin can bind to phagocytes and trigger various oxidative processes in the body (Fernandes et al., 2019).

It is known that melatonin stimulates the release of active oxygen metabolites by immune cells (Honorio-França et al., 2013). The mechanisms by which melatonin influences immune functions involve the participation of other hormones, cytokines, and specific receptors (Pandi-Perumal et al., 2008). Studies with macrophages in experimental models of diabetes and diabetic patients report that melatonin exerts antioxidant action. In animal cells and non-diabetic individuals, it has a pro-oxidative effect (França et al., 2008; Honorio-França et al., 2009; Morceli et al., 2013). However, the effects of melatonin on the oxidative process on placental cells and their action on the maternal–fetal interface have not yet been elucidated. Melatonin may act in the cellular oxidative process by favoring the development of the fetus and the vascularization of the uteroplacental in pregnancies of diabetic mothers. Thus, this study proposed to analyze the cellular oxidative process and the induction of apoptosis in maternal blood and placental cells modulated by melatonin from diabetic mothers.

MATERIALS AND METHODS

A cross-sectional study was performed with blood and placenta from diabetic mothers. The mothers were attended the Diabetes and Pregnancy Facility, School of Medicine Obstetrics Course, UNESP, Botucatu, SP. The local Research Ethics Committee approved this study, and all the women gave informed consent.

Subjects

For analysis of blood and placenta, the pregnant women (18–45 years old) were separated by maternal glycemic status. Pregnant women with diabetes mellitus type 2 (T2DM) were referred to the service with a confirmed diagnosis. The non-diabetic pregnant women were evaluated by a 75-g oral glucose tolerance test (OGTT-75 g-American Diabetes Association [ADA], 2014) and glucose profile (GP; Rudge et al., 2000; Calderon et al., 2007) between the 24th and 28th weeks of pregnancy. Thus, according to the test results, 40 pregnant women were classified into the following groups: the non-diabetic (ND) group (normal 75 g-OGTT and normal GP; n = 20) and the type 2 diabetes mellitus (T2DM) group (abnormal GTT-75 g, prior to pregnancy n = 20) (American Diabetes Association [ADA], 2014).

Independent of diagnosis, the pregnant women continued attending the service. Patients with T2DM were evaluated every 2 weeks until the 32nd week for GP with fasting, pre-and post-prandial glycemic levels for 24 h. In addition, they were treated with physical exercise, a specific diet, and insulin therapy from the beginning of the pregnancy until delivery (Calderon et al., 2007) for glycemic control (Rudge et al., 2000). A glycaemic mean of 120 mg/dL or less was defined as adequate glycaemic control, and a glycaemic mean higher than 120 mg/dL was defined as inadequate glycaemic control. The ND pregnant women did not receive any type of therapy for glycemic control.

These patients were individualized by gestational age at delivery, altered blood pressure, and body mass indexes. In addition, women with gestational age until 20 weeks who received prenatal and delivery care at the Service and signed a Consent Form and delivered in the morning were considered inclusion criteria. The exclusion criteria were women with multiple pregnancies, T1DM, GDM, fetal malformations, and deliveries before the 34th week of gestation.

Blood Sampling and Separation of Blood Cells

Before labor, approximately 8 mL of blood sample was collected into heparinized (25 U/ml) tubes in the morning (8:00 at 10:00 h) at the 36th week of pregnancy. The plasma was retired and maintained at −80°C for the determination of glucose, melatonin, and SOD. The cells were obtained by fractionated with Ficoll-Paque density gradient (density 1.077 g/L; centrifugation 160 × g; 40 min; Pharmacia, Upsala, Sweden) and resuspended independently in serum-free medium 199 at a final concentration of 2 × 106 cells mL⁻¹ and used immediately for assays of superoxide release and apoptosis.

Placenta Sampling and Separation of Cells

Placenta was obtained at delivery and washed with saline solution. A sample was collected along the placenta to remove the villous region with a margin of approximately 2 cm
from the insertion of the umbilical cord, midway between the maternal and fetal sides. The large vessels were removed, leaving only the villous tissue (22,23). The basal plate was carefully dissected from the villous tissue and amniochorion membrane. The isolation of extravillous tissue was adapted from the procedure described for isolating amniochoric cytotrophoblast and removing the extravillous region from the placental border (Calderon et al., 2007; Stenqvist et al., 2008; Vincent et al., 2015). The fragments were stored in liquid nitrogen for later obtaining of cells. The samples (100 mg of tissue/ml) were macerated in PBS with Tween 20 supplemented with protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride; 0.1 mM benzethonium chloride, 10 mM EDTA, 20 U aprotinin, and 0.5% BSA) using a homogenizer Power Gen 125 (Fisher Scientific®). The homogenate was filtered and reserved for MLT and SOD determination, and the sediment (cells) was fractioned by Ficoll-Paque gradient (density 1.077 g/L; centrifugation 160 × g; 40 min; Pharmacia, Uppsala, Sweden). After centrifugation, the cells were collected using a siliconized Pasteur pipet and transferred to tubes. The cells were washed twice with Medium 199 (Sigma Chemical, St. Louis, MO, United States) for superoxide release and apoptosis assays.

**Glucose Determination**

Glucose levels were quantified by the glucose oxidase method (Glucose – analyzer II Beckman, Fullerton, CA, United States). HbA1c was determined by high-performance liquid chromatography (D10™ hemoglobin testing system, BIO-RAD Laboratories, Hercules, CA, United States).

**Determination of Melatonin**

The hormone melatonin (plasma and placenta homogenate) was quantified by the Melatonin ELISA kit (IBL Hamburg, German). The kit has the following characteristics: the lower detection limit was 1.6 pg/ml, and intra-assay and inter-assay coefficients of variation (%) were 3.0–11.4 and 6.4–19.3, respectively. Melatonin extraction was performed by the affinity chromatography method using standardized columns. Columns were placed in glass tubes and centrifuged twice with 1 ml methanol (1 min – 200 × g). Then the columns were washed two times with double distilled water (1 min – 200 × g). After preparation of columns, 0.5 ml of standards, controls, and samples were applied and centrifuged for 1 min at 200 × g. After applying the samples and standards, the columns were washed again with 1.0 ml of 10% methanol for 1 min at 500 × g. Next, the extraction of the eluate containing the hormone melatonin was carried out by adding 1.0 ml of methanol at 200 × g. After obtaining the eluate, the methanol was evaporated using an evaporator centrifuge (speed-vac). The material was reconstituted with 0.15 ml of double distilled water under stirring for 1 min and immediately analyzed. 50 ml of each standard, control, and Colostrum and milk samples were placed in an ELISA plate with 50 ml of melatonin-biotin in each well with 50 ml of antiserum. The plate was incubated at 4°C for 20 h. After this period, the supernatant was discarded, the plate was washed 3 times with wash buffer, and 150 ml of the conjugated enzyme was added. After 120 min of incubation at room temperature, the plate was washed 3 times, 200 ml of the substrate p-nitrophenyl phosphatase (PNPP), and incubated for another 40 min under agitation. After this period, the reaction was blocked with 50 ml of “PNPP stop” solution, and the reading was done in a spectrophotometer for a 405 nm filter. Results were calculated using the standard curve ($R^2 = 0.984$) and expressed in pg/mL (Honorio-França et al., 2013).

**Cells Treatment**

Blood and placental MN cells treated or not with 50 μL of melatonin (MLT − 100 ng/mL final concentration- Honorio-França et al., 2013) were incubated for 24 h (37°C, 5% CO2). After the cells were resuspended in RPMI 1640 medium containing 10% fetal bovine serum (FBS-Sigma, St. Louis, MO, United States), the cells were tested for superoxide release and apoptosis. The culture supernatant was reserved for quantitation of the superoxide enzyme (SOD). For each assay performed, a phagocyte control (2 × 10⁶ cells/ml) was incubated for a similar time, depending on the type of essay in medium 199 or PBS, in the absence of melatonin.

**Superoxide Anion Determination**

Superoxide release was evaluated by method reduction of cytochrome C (Sigma, St Louis, MO, United States; Honorio-França et al., 1997). Blood and placental MN cells treated or not with MLT were incubated for 24 h. After this time, the cells were centrifuged (160 × g, 10 min) and resuspended in PBS containing 2.6 mM CaCl2, 2 mM MgCl2, and cytochrome C. The cells (100 μL) were then incubated on culture plates at 37°C for 1 h. A control of untreated cells was used to evaluate spontaneous release. The reactions were measured by absorbance at 550 nm, and the results are expressed as nmol. O2−. The experiments were performed in duplicate.

**TABLE 1 | Clinical data on the pregnant women non-diabetic (ND) and T2DM (type 2 diabetes mellitus).**

| Parameters | ND | T2DM |
|------------|----|------|
| Age (years) | 27.1 ± 3.8 | 29.5 ± 5.3 |
| Gestational Age (weeks) | 38.0 ± 1.2 | 37.8 ± 0.8 |
| Glucose level (mmol/L) | 4.2 ± 0.7 | 5.9 ± 0.8* |
| HbA1c (%) | 5.2 ± 0.4 | 6.4 ± 0.8* |
| BMI-1 | 27.2 ± 4.2 | 30.3 ± 6.0 |
| BMI-2 | 31.8 ± 7.3 | 34.4 ± 8.9 |
| Hypertension | 10% | 40%* |
| Smoking | 10% | 5%* |
| Physical exercise | 25% | 70%* |
| Placental weight (g) | 612.5 ± 99.4 | 716.6 ± 112.6 |
| Placental Index | 0.162 ± 0.035 | 0.179 ± 0.031* |

HbA1c - Glycated hemoglobin, BMI-1 and BMI-2 (body mass index in the first and third trimesters of pregnancy, respectively).

Data correspond to the median of 40 mothers.

*Placental index is the ratio of placental weight to fetal weight.

*P < 0.05 statistical difference (Student’s t-test).

*P < 0.05 statistical difference (Chi-square test).
Statistical significance was considered when cells from blood and placenta treated or not with melatonin, analyzed qualitative variables (hypertension, smoking, and melatonin, and superoxide dismutase). The chi-square test was applied to analyze the results, and the data were evaluated by Cell Quest software.

**Statistical Analysis**

The Student's t-test was used to evaluate the age, gestational age, BMI, placental weight and index, glucose, glycated hemoglobin, melatonin, and superoxide dismutase. The chi-square test analyzed qualitative variables (hypertension, smoking, and physical exercise). Analysis of variance (one-way ANOVA) and Tukey's tests were used to evaluate the superoxide release, superoxide dismutase (in culture), and apoptosis index of MN cells from blood and placenta treated or not with melatonin. Statistical significance was considered when p < 0.05.

**RESULTS**

Clinical data of the mothers (ND and T2DM) are shown in Table 1. Pregnant women showed similarities in gestational age at birth, maternal age, and weight before pregnancy. Glycated hemoglobin levels were increased in diabetic mothers (Table 1).

The melatonin and superoxide dismutase (SOD) levels were evaluated in both groups' maternal blood and placenta (Figure 1). The melatonin and SOD levels were higher in the maternal blood from diabetic mothers (Figure 1A). In placenta villi, both melatonin and SOD were lower in the diabetic group than in the ND group (Figure 1B). In contrast, in the placental extravillous layer, melatonin and SOD were similar among the groups (Figure 1C).

In culture supernatants from maternal blood MN cells, the SOD levels were lower in the diabetic group. Similar concentrations of the enzyme were observed in cells treated with melatonin in both studied groups. Similar SOD levels were later observed in MN cells in the placenta villi, irrespective of melatonin treatment. A reduction in SOD levels was observed in the MN cell culture supernatants from the placenta extravillous layer of diabetic mothers compared to ND mothers. Similar enzyme values were found in the culture supernatants when these cells were incubated with melatonin, regardless of the glycemic level of the study subjects (Table 2).

Superoxide release was higher in MN cells from maternal blood from diabetic mothers than in MN cells from ND mothers. In the non-diabetic group, blood MN cells stimulated with melatonin presented higher superoxide release than untreated cells (p < 0.05). However, melatonin did not increase superoxide release in blood MN cells in the hyperglycemic group (Figure 2A).

Irrespective of placental section, superoxide release was higher in MN cells from the placental villous layer of diabetic mothers. Melatonin increased superoxide release in cells from the placental villous layer (Figure 2B). However, superoxide release was lower in MN cells from placenta extravillous from the T2DM group (Figure 2C). The highest superoxide levels were observed in phagocytes of hormone-treated non-diabetic mothers (Figure 2C).

The placenta villous/extravillous superoxide release ratio is shown in Figure 3A. It was observed that there was an increase in the anion release ratio between the MN cells of the different placental layers in the diabetic group compared to the ND group. In contrast, melatonin treatment reduced the placenta villous/extravillous superoxide ratio.

Figure 3B shows the placenta villous/extravillous SOD ratios. There was a reduction of the enzyme in the placenta villous/extravillous ratio in the diabetic group compared to the ND group. However, there was a significant increase villous/extravillous SOD ratio when treated with melatonin.

The SOD/O$_2^-$ ratio in the maternal blood and the placental villous and extravillous layers in both groups are shown in Table 3. Blood MN cells and placenta villous were lower in T2DM. Melatonin treatment increased the SOD/O$_2^-$ ratio in the T2DM group with values similar to those found in normoglycemic mothers. There was no difference between the groups studied in the SOD/O$_2^-$ ratio in the placental extravillous layer (Table 3).

Higher apoptosis rates were found in maternal blood cells from the diabetic group relative to the non-diabetic group. Melatonin treatment reduced the apoptosis rates in this group relative to the ND group. In the placenta villous, the apoptosis rates were lower in the T2DM group irrespective of melatonin stimulation. In both groups, there were no significant differences between the apoptosis indices of MN cells from placenta extravilli (Table 4).

**DISCUSSION**

Hyperglycemia maternal promotes the production of reactive oxygen species (ROS), resulting in oxidative stress, which
can contribute to the proinflammatory environment typical of diabetes (Cvitic et al., 2014) and placental hypervascularization, with alterations in vasculogenesis and VEGF-R1 and R2 receptors (Pietro et al., 2010). In this work, hyperglycemia was able to alter the balance between superoxide anion production and the enzyme superoxide dismutase (SOD) in maternal blood and the placenta of diabetic mothers. These alterations were reflected in the mechanisms of induction of apoptosis and were modulated by the hormone melatonin.

Melatonin assessed in the morning in diabetic mothers had higher levels in maternal blood and lower in placental villi. However, maternal blood and placenta melatonin concentrations of women are variable. Some authors report higher hormone concentration in the blood (Ejaz et al., 2021) and tissue (Lanoix et al., 2012), while others show lower levels (Bouchlariotou et al., 2014) similar to those values found in blood and placenta in this study and colostrum (Morceli et al., 2013) from diabetic mothers.

The blood MN cells of diabetic mothers presented an increase in superoxide anion, lower release of the enzyme superoxide dismutase, and reduction in the SOD/O$_2^-$ ratio, suggesting alterations in the balance between the prooxidant and antioxidant systems. The free radical generation by mononuclear cells, including the superoxide anion, is an important defense mechanism against infectious diseases (França et al., 2011;...

**TABLE 2** | Superoxide dismutase (SOD) levels in the culture supernatant of maternal blood cells, placenta villi, and placenta extravilli treated or not with melatonin from diabetic mothers.

| SOD (UI)                  | ND       | T2DM     |
|---------------------------|----------|----------|
| Maternal blood            |          |          |
| MLT (−)                   | 14.8 ± 6.3 | 4.71 ± 1.2$^*$ |
| MLT (+)                   | 15.7 ± 7.9 | 18.2 ± 6.1$^*$ |
| Placenta villous          |          |          |
| MLT (−)                   | 18.3 ± 5.9 | 17.2 ± 3.4 |
| MLT (+)                   | 15.8 ± 7.1 | 13. ± 6.8|
| Placenta extravilli       |          |          |
| MLT (−)                   | 20.2 ± 5.4 | 9.3 ± 5.7$^*$$^†$ |
| MLT (+)                   | 21.9 ± 8.9 | 19.2 ± 8.3$^*$ |

The results represent the mean and standard deviation of 10 samples.
MN, Mononuclear cells (MN); MLT, melatonin.
P < 0.05 statistical difference (ANOVA test) * comparing the groups considering the same treatment and type of sample; $^*$ comparing untreated cells with cells treated with melatonin, considering the same group and sample; $^†$ comparing between villous and extravillous placental layers considering the same treatment and group.
FIGURE 2 | Release of superoxide (O2−) by maternal blood phagocytes (A), villous placenta (B), and extravillous placenta (C) treated or not with melatonin from diabetic pregnant women. The results represent the mean and standard deviation of 10 MN cell samples from different mothers in each group. *P < 0.05 statistical difference (ANOVA) comparing the groups, considering the same treatment and type of sample; #p < 0.05, comparing cells treated with untreated melatonin, considering the same group and sample. Non-diabetic (ND); Type 2 Diabetes Mellitus (T2DM); melatonin (MLT); mononuclear cells (MN).

Fagundes et al., 2018), although the balance between the pro- and antioxidant mechanisms is also necessary since elevated levels of free radicals cause damage to cells that may result in the activation of cell death pathways (Benirschke, 2000; Maritim et al., 2003; Ferrari et al., 2011; Fernandes et al., 2019).

Various mechanisms have been proposed for the generation of reactive oxygen species. In diabetic patients, glucose oxidation may be the main source of free radicals (França et al., 2008; Ferrari et al., 2011). Hyperglycemia leads to lipid peroxidation by a superoxide-dependent pathway, resulting in the generation and release of free radicals (Rui et al., 2016). Additionally, the interaction of glucose with proteins that promote advanced glycosylation end products contributes to the excess free radical formation (Lappas et al., 2011).

Melatonin increased the release of superoxide in the non-diabetic group and reduced the release of this anion in MN cells of the diabetic group. This reduction affected the SOD/O₂⁻ ratio, resulting in values similar to those found in the control group.

The melatonin functions in humans are still partially understood. Melatonin can be associated with mononuclear
cells, having even been related to the oxidative processes of the organism (França et al., 2008). Melatonin, depending on the dose administered, may have an antioxidative effect, including the scavenging of radicals (França et al., 2008) or pro-oxidative function (Hara et al., 2013; Honorio-França et al., 2013).

Melatonin increases superoxide production in MN phagocytes of non-diabetic mothers but not in the phagocytes of diabetic women. Maternal hyperglycemia alters the functional activity of these cells, and its effects are probably attributed to non-inflammatory processes, with lower superoxide release (Morceli et al., 2013). Inadequate stimulation of the activity of MN cells by melatonin, due to a failure in the prooxidant mechanisms, indicates an antioxidant effect related to diabetes (Reiter et al., 2008). Similar results were reported in diabetes models induced by the diabetogenic drug alloxan (Pawlak et al., 2005; Devi et al., 2008; França et al., 2008).

Alterations in the pro- and antioxidant mechanisms were also shown in the placenta being linked with its layers (extravillous and villous layers). The maternal layer showed a lower concentration of SOD enzyme. The presence of melatonin restored the levels of this enzyme with values similar to those of the control group. In addition, there was an increase in superoxide in the fetal layer and a reduction in the SOD/O2 ratio. In the presence of melatonin, there was a reduction in superoxide. The SOD/O2 ratio presented values similar to those of the control group, suggesting that in both layers of the placenta, melatonin could reduce oxidative stress, possibly caused by hyperglycemia.

Experimental studies in diabetic pregnancies have associated increased oxidative stress and reduced antioxidant capacity with abnormalities in the structure and function of the placenta (White et al., 2002). Thus, oxidative stress occurs in women with diabetic pregnancy and probably compromises antioxidant defense mechanisms and increases the generation of free radicals (Biri et al., 2009).

As a barrier between the mother and fetus, the placenta targets environmental changes (Radaelli et al., 2003). This organ can alter maternal blood cell and cytokine levels before transferring
them to the fetus, and the inflammatory environment influences this mechanism due to hyperglycemia (Hara et al., 2013). Further, there is an impact of maternal diabetes on fetal vascular growth and angiogenesis with placental hypervascularization (Cvitic et al., 2014). These changes in the fetoplacental vasculature in response to maternal diabetes may also imply potential differences in the fetus's vasculature. Maternal metabolic alterations resulting from hyperglycemia change the uterine environment and may lead to an abnormal fetal growth pattern (Catalano et al., 1999). The key to these alterations is maternal hyperglycemia, with consequent fetal hyperglycemia and hyperinsulinemia, inducing hypoxia, inflammation, and oxidative stress in the intrauterine environment. In this study, changes in oxidative stress found in maternal blood were reflected in the placenta and were probably directed to the fetus.

A relevant result is that the rate of superoxide release (placenta villous/extravillous) was higher in the placenta of T2DM, and melatonin was able to reduce this superoxide rate and increase the rate of SOD. Furthermore, it is known that melatonin can act in the removal of free radicals (Xia et al., 2019) and diabetes control

### TABLE 3 | Superoxide dismutase (SOD) and release of superoxide anion (O2−) rates (SOD/O2−) in the culture supernatant of MN cells of blood and placenta treated or not by melatonin of diabetic mothers.

| Parameters       | ND       | T2DM     |
|------------------|----------|----------|
| Maternal blood   | MLT (−)  | 10.9 ± 4.7 | 2.7 ± 1.3^g  |
|                  | MLT (+)  | 8.8 ± 3.7  | 11.0 ± 5.7  |
| Placenta villous | MLT (−)  | 12.4 ± 4.3  | 4.1 ± 1.7^*  |
|                  | MLT (+)  | 14.0 ± 6.9  | 16.5 ± 5.7^g  |
| Placenta extravillous | MLT (−) | 11.5 ± 3.5  | 11.6 ± 2.4^t  |
|                  | MLT (+)  | 9.6 ± 4.9^†  | 7.5 ± 3.5^†  |

The results represent the mean and standard deviation of 10 samples. MN, Mononuclear cells; MLT, melatonin (MLT).

P < 0.05 statistical difference (ANOVA test) * comparing the groups considering the same treatment and type of sample; † comparing untreated cells with cells treated with melatonin, considering the same group and sample; ‡ comparing between villous and extravillous placental layers considering the same treatment and group.

### TABLE 4 | Viable index (%) and apoptosis (%) of MN cells treated by melatonin from maternal blood and placenta from the non-diabetic (ND) and Type II Diabetes Mellitus (T2DM) groups.

| MN cells          | ND       | T2DM     |
|-------------------|----------|----------|
|                   | Viable   | Apoptosis| Viable   | Apoptosis|
| Maternal blood    | MLT (−)  | 78.9 ± 9.1 | 21.1 ± 8.5 | 68.6 ± 12.7 | 41.4 ± 11.0^g  |
|                   | MLT (+)  | 80.4 ± 6.8 | 19.6 ± 5.7 | 82.9 ± 4.6^* | 17.1 ± 3.7^*  |
| Placenta villous  | MLT (−)  | 76.5 ± 16.4 | 33.0 ± 5.8 | 82.5 ± 6.4 | 16.1 ± 5.7^g  |
|                   | MLT (+)  | 81.4 ± 9.1 | 26.1 ± 6.6 | 78.7 ± 7.0 | 18.8 ± 5.4^g  |
| Placenta extravillous | MLT (−) | 79.4 ± 5.1 | 21.7 ± 11.4^† | 73.7 ± 11.0 | 23.8 ± 8.9^†  |
|                   | MLT (+)  | 78 ± 5.0  | 22.1 ± 11.4 | 75.4 ± 10.7 | 22.8 ± 11.1  |

The results represent the mean and standard deviation of 10 samples. MN, Mononuclear cells; MLT, melatonin.

P < 0.05 statistical difference (ANOVA test) * comparing the groups considering the same treatment and type of sample; † comparing untreated cells with cells treated with melatonin, considering the same group and sample; ‡ comparing between villous and extravillous placental layers considering the same treatment and group.
and contributes to the supply of oxygen and nutrients to increase placental efficiency (Lemley and Vonnahme, 2017).

Melatonin plays a vital role in protecting female reproduction. Lower implantation rates, pregnancy deficiencies, higher incidence of menstrual irregularities, infertility, and miscarriage in women are often associated with changes in melatonin levels in normal uterine and placental tissues. This hormone, well-established by the pharmaceutical industry, has been used as a drug in treating several diseases and appears to be effective in treating pre-eclampsia. Thus, considering its lack of toxicity, this study corroborates the potential benefits of melatonin in the reproduction of diabetic mothers and may contribute to its future therapeutic use to minimize the pro-oxidative effects caused by hyperglycemia since melatonin acts, in cells and tissues, against oxidative damage potentially improve maternal and neonatal quality of life.

It should be considered that these data were evaluated during a collection period, which can be considered a limitation of this study. Furthermore, it is necessary to continue investigations focusing on other factors and interactions with other hormones or bioactive components that may be important for the fetal-placental unit.

These data suggest that hyperglycemia could alter the balance between superoxide anion production and superoxide dismutase (SOD) enzyme in maternal blood and the placenta of diabetic mothers. These changes reflected in the apoptosis induction mechanisms and were modulated by the hormone melatonin. These results reinforce the importance of the melatonin hormone in the control of oxidative stress and reduction of apoptosis in the maternal blood and the control of apoptosis in trophoblastic cells, which may probably favor maternal-fetal tolerance and the vascularization of the uteroplacental in diabetic mothers.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research Ethics Committee of School of Medicine Obstetrics Course, UNESP, Botucatu, SP. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ML carried out the assay, participated in the sequence alignment, and drafted the manuscript. DF and AQ participated in collecting samples, carried out the assays, and helped to draft the manuscript. IC participated in the design of the study and helped to draft the manuscript. EF participated in the design of the study and coordination and helped to draft the manuscript. AH-F conceived the study, carried out the assays, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

Funding for this research was provided by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-No: 303983/2016-7, No: 403383/2016-1, and 305725/2018-1).

REFERENCES

American Diabetes Association [ADA] (2014). Diagnosis and classification of diabetes mellitus. Diab. Care 37, 81–90. Arendt, J., and Skene, D. (2005). Melatonin as a chronobiotic. Sleep Med. Rev. 9, 25–39. Basić, D., Popović, S., Ristić, P., and Arsenijević, N. N. (2006). Analysis of cycloheximide-induced apoptosis in human leukocytes, fluorescence microscopy using annexin V/propropidium iodide versus acridine orange/ethidium bromide. Cell Biol. Int. 30, 924–932. doi: 10.1016/j.cellbi.2006.06.016 Benirschke, K. (2000). Pathology of the Human Placenta, 4 Edn. New York, NY: Springer-Verlag. Birri, A., Korucuoglu, U., Ozcan, P., Aksakal, N., Turan, O., and Himmetoglu, O. (2009). Effect of different degrees of glucose intolerance on maternal and perinatal outcomes. J. Matern. Fetal Neonatal Med. 22, 473–478. doi: 10.1080/1476705080261344 Bouchlariotou, S., Liakopoulos, V., Giannopoulos, M., Arampatzis, S., Eleftheriadis, T., Mertens, P. R., et al. (2014). Melatonin secretion is impaired in women with preeclampsia and an abnormal circadian blood pressure rhythm. Rent. Fisiol. 36, 1001–1007. doi: 10.3109/08860622X2014.926216 Calderon, I. M. P., Damasceno, D. C., Amorim, R. L., Costa, R. A., Brasil, M. A., and Rudge, M. V. (2007). Morphometric study of placental villi and vessels in women with mild hyperglycemia or gestational or overt diabetes. Diabetes Res. Clin. Pract. 78, 65–71. doi: 10.1016/j.diabres.2007.01.023 Catalano, P., Huston, L., Anini, S., and Kalhan, S. C. (1999). Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and GDM. Am. J. Obstet. Gynecol. 180, 903–916. Collins, A. R., Raslová, K., Smorovská, M. P., Petrovská, H., Ondrusová, A., Vohnout, B., et al. (1998). DNA damage in diabetes. Correlation with a clinical marker. Free Radic. Biol. Med. 25, 373–377. doi: 10.1016/s0891-5849(98)00537-3 Cvitic, S., Desoye, G., and Hiden, U. (2014). Glucose, insulin, and oxygen interplay in placental hypertovascularisation in diabetes mellitus. BioMed Res. Int. 34, 480–484. doi: 10.1155/2014/145846 Devi, M. M. S., Suresh, Y., and Das, U. N. (2008). Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin. J. Pineal Res. 29, 108–115. doi: 10.1034/j.1600-079x.2000.290207.x Ejaz, H., Figaro, J. K., Woolner, A. M. F., Thottakam, B. M. V., and Galley, H. F. (2021). Maternal serum melatonin increases during pregnancy and falls immediately after delivery implicating the placenta as a major source of melatonin. Front. Endocrinol. 11:623038. doi: 10.3389/fendo.2020.623038 Espinosa-Diez, C., Miguel, V., Mennerich, D., Kietzmann, T., Sánchez-Péres, P., Cadenas, S., et al. (2015). Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 6, 183–197. doi: 10.1016/j.redox.2015.07.008 Fagundes, D. L. G., França, E. L., Gonzatti, M. B., Rudge, M. V., Calderon, I. M. P., and Honorio-França, A. C. (2018). The modulatory role of cytokines IL-4 and IL-17 in the functional activity of phagocytes in diabetic pregnant women. APMIS 126, 56–64. doi: 10.1111/apm.12772
Louis et al. Melatonin Effects in Blood and Placental Cells

Sudnikovich, E. J., Maksimchik, Y. Z., Zabrodskaya, S. V., Kubyshin, V. L., Lapshina, E. A., and Bryszewska, M. (2007). Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes rats. *Eur. J. Pharmacol.* 569, 180–187. doi: 10.1016/j.ejphar.2007.05.018

Vincent, Z. L., Mitchell, M. D., and Ponnampalam, A. P. (2015). Regulation of MT1-MMP/MMP-2/TIMP-2 axis in human placenta. *J. Inflamm. Res.* 8, 193–200. doi: 10.2147/JIR.S88039

White, V., Jawerbaum, A., Sinner, D., Pustovrh, C., Capobianco, E., and González, E. (2002). Oxidative stress and altered prostanoid production in the placenta of streptozotocin-induced diabetic rats. *Reprod. Fertil. Dev.* 14, 117–123. doi: 10.1071/rd01032

Xia, Y., Chen, S., Zeng, S., Zhao, Y., Zhu, C., Deng, B., et al. (2019). Melatonin in macrophages biology, current understanding and future perspectives. *J. Pineal Res.* 66:e12547. doi: 10.1111/jpi.12547

Zimmermann, K. C., Bonzon, C., and Green, D. R. (2001). The machinery of programmed cell death. *Pharmacol. Ther.* 92, 57–70.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Louis, França, Queiroz, Calderon, França and Honorio-França. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.